SuperworthASP Isotopes ASPI
- Market cap
- $298.2M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 9.7×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $30.9M
- growth n/m, growth from a base too small to compare
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −28.0%
ASP Isotopes trades at 9.7× sales. Its trailing earnings are negative, so it has no PE. Revenue was $30.9M over the last twelve months.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $433K | $840.4K | $1M | $1.1M | $1.2M+176% | $1.1M+31% | $1.2M+17% | $4.9M+350% | $16.7M+1295% | $4.2M+279% | $5.1M+328% | |
| Cost of revenue | $0 | $294.1K | $561.5K | $601.3K | $793.7K | $588.1K+100% | $774.8K+38% | $626.2K+4% | $4.5M+463% | $14.6M+2378% | $2.5M+225% | $3.6M+482% |
| Gross profit | $0 | $139K | $278.9K | $421K | $294K | $605.1K+335% | $326.8K+17% | $572.1K+36% | $423.2K+44% | $2.1M+244% | $1.7M+410% | $1.5M+159% |
| R&D | $239.2K−68% | $65.2K−20% | $215.1K+4% | $473.3K+87% | $1M+333% | $1.4M+2073% | $1.5M+611% | $879.9K+86% | $3.1M+200% | $6.8M+384% | $5.3M+244% | $6.8M+676% |
| SG&A | $3.7M+207% | $4.1M+197% | $5.9M+67% | $7.4M+81% | $4.7M+27% | $6.8M+67% | $6.7M+15% | $11.7M+58% | $12.3M+162% | $17.5M+157% | $21.3M+216% | $28.9M+147% |
| −$3.9M+102% | −$4M+176% | −$5.8M+56% | −$7.5M+72% | −$5.4M+38% | −$7.6M+90% | −$8M+37% | −$12M+61% | −$15M+176% | −$25M+227% | −$24.9M+213% | −$34.2M+186% | |
| Interest expense | $0 | $118.5K | $13.8K | $69.1K | $91K | $85K−28% | $87.2K+532% | $81.8K+18% | $146.1K+61% | $260K+206% | $1.7M+1884% | $1.8M+2069% |
| Pre-tax income | −$4.2M | −$4.2M | −$7M+94% | −$8.9M+107% | −$7.4M+74% | −$9.1M+117% | −$8.5M+22% | −$75.1M+747% | −$12.8M+74% | −$63.1M+596% | −$26.7M+213% | −$34.1M−55% |
| $0 | −$6.1K | −$47.6K | $13.8K | −$8.4K | $153.7K | −$70.7K+49% | $95.2K+592% | $73.6K | $183.9K+20% | −$31K−56% | −$97K | |
| Net income | −$4.2M+116% | −$4.2M+220% | −$7M+93% | −$8.9M+107% | −$7.4M+74% | −$9.2M+121% | −$8.5M+22% | −$75.2M+746% | −$12.9M+75% | −$63.3M+587% | −$7.1M−16% | −$34M−55% |
| −$0.14+133% | −$0.10+67% | −$0.16+33% | −$0.24+71% | −$0.12−14% | −$0.14+40% | −$0.12−25% | −$1.03+329% | −$0.15+25% | −$0.61+336% | −$0.06−50% | −$0.27−74% | |
| 31.1M+4% | 42.3M+99% | 44.6M+53% | 49.1M+65% | 61.5M+98% | 67.3M+59% | 69.5M+56% | 73M+49% | 88.6M+44% | 103.9M+54% | 121M+74% | 122.7M+68% |
EPS, diluted: 11 periods, Q1 FY22 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Chemicals nearest ASP Isotopes' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ASPIASP Isotopes | $298.2M | n/m | n/a | 9.7× | n/m | n/m | |
| NAGENiagen Bioscience | $192.3M | 13.5× | 27.0× | 1.5× | +11% | 12.4% | |
| FTKFlotek Industries | $865.7M | 24.1× | 27.6× | 3.0× | +37% | 13.0% | |
| FTLFFitlife Brands | $78.4M | 13.5× | 15.3× | 0.8× | +61% | 6.2% | |
| CRONCronos | $1.2B | 16.8× | 25.0× | 6.9× | +37% | 39.1% | |
| ROGRogers | $2.2B | 71.4× | 34.3× | 2.7× | +5% | 3.7% | |
| BTMDbiote | $38.4M | 10.7× | 12.3× | 0.2× | −8% | 3.2% | |
| NGVTIngevity | $2.4B | 47.4× | 19.9× | 2.1× | −4% | 4.7% | |
| IOSPInnospec | $2.4B | 20.1× | 22.3× | 1.3× | +3% | 6.6% | |
| FULFuller H B | $2.7B | 13.8× | 22.9× | 0.8× | +1% | 5.6% | |
| WDFCWD 40 | $2.9B | 32.3× | 39.2× | 4.2× | +10% | 13.2% | |
| Peer median | $1.7B | 18.4× | 23.9× | 1.8× | +8% | 6.4% |
Investors who own it
Investors we follow who held ASP Isotopes at the end of Jun 30, 2026, from their 13F filings.
- Polen CapitalPolen Capital0.0% of portfolioadded
More on ASP Isotopes
Each number over time
Its groups
About
- Industry
- Chemicals
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .